Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. by Crosby, T et al.
Long-term results and recurrence patterns
from SCOPE-1: a phase II/III randomised trial
of definitive chemoradiotherapy þ /
cetuximab in oesophageal cancer
T Crosby1, C N Hurt*,2, S Falk3, S Gollins4, J Staffurth1, R Ray2, J A Bridgewater5, J I Geh6,
D Cunningham7, J Blazeby8, R Roy9, T Maughan10, G Griffiths11 and S Mukherjee10
1Velindre Cancer Centre, Velindre Hospital, Cardiff CF14 2TL, UK; 2Wales Cancer Trials Unit, Cardiff University, Cardiff CF14 4YS,
UK; 3Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol BS2 8ED, UK; 4North
Wales Cancer Treatment Centre, Conwy and Denbighshire NHS Trust, Rhyl LL18 5UJ, UK; 5UCL Cancer Institute, University
College London, London WC1E 6BT, UK; 6Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust
Birmingham B15 2GW, UK; 7The Royal Marsden Hospital NHS Foundation Trust, London SM2 5PT, UK; 8Centre for Surgical
Research, University of Bristol, Bristol BS8 2PS, UK; 9Diana Princess of Wales Hospital, Northern Lincolnshire and Goole NHS
Foundation Trust, Grimsby DN33 2BA, UK; 10CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford
OX3 7DQ, UK and 11Southampton Clinical Trials Unit, University of Southampton, Southampton SO16 6YD, UK
Background: The SCOPE-1 study tested the role of adding cetuximab to conventional definitive chemoradiotherapy (dCRT), and
demonstrated greater toxicity and worse survival outcomes. We present the long-term outcomes and patterns of recurrence.
Methods: SCOPE-1 was a phase II/III trial in which patients were randomised to cisplatin 60mgm 2 (day 1) and capecitabine
625mgm 2 bd (days 1–21) for four cycles þ / cetuximab 400mgm 2 day 1 then by 250mgm 2 weekly. Radiotherapy
consisted of 50Gy/25# given concurrently with cycles 3 and 4. Recruitment was between February 2008 and February 2012, when
the IDMC recommended closure on the basis of futility.
Results: About 258 patients (dCRT¼ 129; dCRTþ cetuximab (dCRTþC)¼ 129) were recruited from 36 centres. About 72.9%
(n¼ 188) had squamous cell histology. The median follow-up (IQR) was 46.2 (35.9–48.3) months for surviving patients. The median
overall survival (OS; months; 95% CI) was 34.5 (24.7–42.3) in dCRT and 24.7 (18.6–31.3) in dCRTþC (hazard ratio (HR)¼ 1.25, 95%
CIs: 0.93–1.69, P¼ 0.137). Median progression-free survival (PFS; months; 95% CI) was 24.1 (15.3–29.9) and 15.9 (10.7–20.8) months,
respectively (HR¼ 1.28, 95% CIs: 0.94–1.75; P¼ 0.114). On multivariable analysis only earlier stage, full-dose RT, and higher
cisplatin dose intensity were associated with improved OS.
Conclusions: The mature analysis demonstrates that the dCRT regimen used in the study provided useful survival outcomes
despite its use in patients who were largely unfit for surgery or who had inoperable disease. Given the competing risk of systemic
and local failure, future studies should continue to focus on enhancing local control as well as optimising systemic therapy.
Definitive chemoradiotherapy (dCRT) is an important treatment
option for localised oesophageal cancer, and is considered a
standard of care for patients with oesophageal squamous cell
carcinoma. Long-term outcomes from dCRT, from large prospec-
tive clinical trials incorporating a modern conformal radiotherapy
delivery protocol, QOL, and a robust radiotherapy quality
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assurance programme (RTQA) have not previously been reported.
This information is important to allow patients to make an
informed choice regarding treatment options, especially as non-
randomised data show that QOL may return to normal more
quickly following dCRT and is better in the longer term compared
with surgery (Rees et al, 2015).
Cancer Research UK SCOPE-1 trial was a randomised control
phase II/III trial, which compared conventional cisplatin–
capecitabine-based dCRT with or without addition of cetuximab.
The addition of cetuximab to radiotherapy for head and neck
cancer had previously shown a significant survival benefit (Bonner
et al, 2006). Following advice from the Independent Data
Monitoring Committee (IDMC), SCOPE-1 was stopped at the
phase II stage after 258 patients were randomised from 36 centres
across the UK between February 2008 and January 2012, because
the trial met the criteria for futility. The initial publication in 2013,
after a median follow-up of 16.8 months in surviving patients (IQR
11.2–24.5), reported a statistically significant overall survival (OS)
detriment in the cetuximab arm (median 25.4 months (95% CIs:
20.5–37.9) vs 22.1 months (15.1–24.5); adjusted hazard ratio (HR)
1.53 (95% CI 1.03–2.27); P¼ 0.035; Crosby et al, 2013).
In this final report, we have looked at the long-term outcomes in
the SCOPE-1, with detailed analysis of secondary end points, patterns
of failure, and implications for future research. ISRCTN: 47718479.
MATERIALS AND METHODS
The trial design, treatments, eligibility criteria, and follow-up were
previously reported in detail (Hurt et al, 2011; Crosby et al, 2013).
In summary, the trial included patients with non-metastatic,
histologically confirmed carcinoma of the oesophagus (adenocar-
cinoma, squamous cell, or undifferentiated; WHO status 0–1; stage
I–III disease; American Joint Committee on Cancer, 6th edition)
and who had been selected to receive dCRT and randomly assigned
them to receive dCRT alone or dCRT with cetuximab
(400mgm 2 on day 1 followed by 250mgm 2 weekly).
Definitive chemoradiotherapy consisted of cisplatin 60mgm 2
(day 1) and capecitabine 625mgm 2 bd twice daily (days 1–21)
for four cycles; cycles 3 and 4 were given concurrently with 50Gy
in 25 fractions of radiotherapy. Follow-up was at 24 weeks, then
every 3 months during the first year, every 4 months during the
second year, and yearly thereafter for a minimum of 5 years from
randomisation, during which time RTOG/EORTC late radiation
morbidity scores (Radiation Therapy Oncology Group, 2007) were
collected. The primary end point was the proportion of patients
with treatment failure-free survival (TFFS, defined as still alive with
no evidence of residual malignancy in the endoscopic biopsy
sample and no evidence of disease progression outside the
radiotherapy field on CT scan) at week 24 for the phase II stage
and OS (time to event) for the phase III stage of the trial, both of
which were measured from randomisation. Secondary end points
included local and distant progression-free survival (LPFS and
DPFS), patterns of first progression, and late toxicity. Distant
progression-free survival was defined as time to progression with
metastases or death by any cause. Local progression-free survival
was defined as either time to progression within the RT volume
(infield) or death by any cause, or outside the RT volume but
within the region (outfield) or death by any cause. QOL data were
collected up to 24 months and have been reported elsewhere (Rees
et al, 2015). The trial was approved by a UK multi-centre ethics
committee and obtained individual informed consent from all
participants. The trial protocol and radiotherapy guideline can be
found in Supplementary Materials 1 and 2, respectively.
All statistical analyses were pre-planned and conducted using
Stata SE 14 (StataCorp, College Station, TX, USA). All analyses
were performed according to the intention-to-treat principle and
included all randomly assigned patients. Follow-up time distribu-
tions were estimated using the reverse Kaplan–Meier method
(Schemper and Smith, 1996) with patients censored at date of
death or last trial assessment. We calculated % of total dose (actual
total dose divided by protocol total dose) and % dose intensity
(actual dose intensity (dose per unit time) divided by protocol dose
intensity) for each protocol drug as measures of compliance. As
has been done elsewhere (Loibl et al, 2011), patients who
progressed or died during the treatment period had denominators
calculated up to the point where they progressed or died. Likewise
for radiotherapy we calculated % of full protocol dose received by
each patient and for those who progressed or died during the
treatment period, the denominator was calculated up to the point
where they progressed or died. We calculated survival from date of
randomisation to when an event occurred, that is, progression or
any death for PFS, and any death for OS. Patients who were event
free were censored at the time they were last known to be event
free. We estimated event time distributions with the Kaplan–Meier
method and compared OS and PFS with HRs from Cox regression
in univariable models and multivariable models. In the multi-
variable models we included all variables thought a priori to
potentially have a prognostic effect and included recruitment
centre as a random frailty effect. The consistency of the main
univariable treatment arm effect was assessed across subgroups
using HR plots and the significance of treatment arm-subgroup
variable interaction terms in Cox models. We tested the
proportional hazards assumption of each model with Cox-Snell
residuals and Schoenfeld’s global test. We did not adjust for having
previously looked at the HRs, as survival was a secondary end point
to the phase II trial.
RESULTS
Study population. The study population was described in detail in
the first report and Figure 1; (Crosby et al, 2013). In summary,
median age was 66.7 (IQR: 60.9–72.9), 56.2% (n¼ 145) were male,
Assessed for eligibility (n= 540)
Excluded (n=282)
Not meeting inclusion criteria (n=213)
Declined (n=66)
Other reasons (n=3)
Allocated to cetuximab (n=129) Allocated to no cetuximab (n=129)
Randomised (n=258)
Figure 1. Flow diagram of trial participants.
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50.8% (n¼ 131) were WHO PS 0 (rather than 1), 60.1% (n¼ 155)
had stage III disease, 72.9% (n¼ 188) had squamous cell type, and
the median disease length was 5 cm (IQR: 4–7.5). The main reason
for no surgery was local extent of disease (47.3%, n¼ 122). T stage:
T1 3.5% (n¼ 9), T2 18.2% (n¼ 47), T3 63.2% (n¼ 163), T4 15.1%
(n¼ 39). N stage: N0 33.3% (n¼ 86), N1 66.7% (n¼ 172).
Median follow-up was 46.2 (IQR: 35.9–48.3) months for surviving
patients. This was balanced across trial arms with median times of
45.2 (IQR: 35.8–48.2) and 46.8 (IQR: 36.4–48.8) months in the dCRT
only and dCRTþC arms, respectively (Figure 2A).
Compliance. Significantly more patients completed all four cycles
of cisplatin and capecitabine in the dCRT-only group (Crosby et al,
2013). More patients in the dCRT group received X75% of the
total protocol dose of capecitabine (72.1 (93 out of 129) vs 62.8%
(81 out of 129), w2¼ 2.542, P¼ 0.111). The proportion of patients
receiving X75% of the full protocol cisplatin dose intensity was
similar in both trial arms (dCRT: 71% (91 out of 129); dCRTþC:
71% (92 out of 129); Supplementary Figure S1). This was mainly
due to a larger proportion of patients in the dCRTþC group
receiving full cisplatin dose in the second cycle of chemotherapy.
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Figure 2. Kaplan–Meier curves of follow-up and survival by treatment group. (A) Follow-up (reverse Kaplan–Meier). (B) Overall survival. (C)
Progression-free survival. (D) Local progression-free survival (infield). (E) Local progression-free survival (outfield). (F) Distant progression-free
survival.
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Significantly more patients in the dCRT group received the full
protocol dose of radiotherapy (90.7 (117 out of 129) vs 79.1% (102
out of 129), w2¼ 6.796, P¼ 0.009). Six patients died (three due to
oesophageal cancer, one sepsis, one stroke, and one vascular
disorder of intestine) prior to the end of the treatment period.
Toxicities. The RTOG/EORTC late radiation morbidity scores are
shown in Supplementary Table S1. Assessment completion rates
were high with scores being obtained in between 91.5% (214 out of
234) at 6 months and 87.9% (123 out of 140) at 24 months. Rates
of oesophageal late radiation morbidity were initially slightly
higher in the dCRT arm reflecting the higher doses achieved in that
arm. However, across arms the rates of worst grade of any residual
toxicity were: 9.3% (20 out of 214) grade 1, 6.5% (14 out of 214)
grade 2, and 0.5% (1 out of 214) grade 3 at 6 months and this
dropped to only 2.4% (3 out of 123) grade 1 at 24 months.
Overall survival. The mature OS analysis (Table 1 and Figure 2B)
demonstrates the median survival in the dCRT arm to be 34.5
months (95% CI: 24.7–42.3) vs 24.7 months (95% CI: 18.6–31.3) in
the dCRTþC arm. With prolonged follow-up, the HR was no longer
statistically significant in either univariable or multivariable analysis
(1.25 (95% CIs: 0.93–1.69, P¼ 0.137) and 1.15 (95% CIs: 0.84–1.57,
P¼ 0.388), respectively). Three-year OS was 47.2% (95% CIs: 38.2–
55.7) in the dCRT-only arm and 37.6% (95% CIs: 29.1–46.0) in the
dCRTþC arm. In patients receiving conventional dCRT: with
squamous cell subtype, the median OS was 35.9 months (95% CI:
24.7–44.0; n¼ 96, 3-year OS: 47.8% (95% CI: 37.1–57.6%)); in the
adenocarcinoma subtype the median OS was 25.8 months (95% CIs:
12.5–46.6; n¼ 32; 3-year OS: 43.8% (95% CIs: 26.5–59.8%)).
Higher stage, less than full protocol radiotherapy dose, and
lower cisplatin dose intensity were associated with worse survival
in multivariable analysis (Table 1). The better survival in the dCRT
arm was consistent across most subgroups of baseline character-
istics other than in females and those with disease length X8 cm
(Figure 3) and only the sex treatment arm interaction term was
significant in Cox models (z¼ 2.58, P¼ 0.010). In females the HR
for treatment effect was 0.81 (95% CI: 0.50–1.31), whereas in males
it was 1.87 (95% CIs: 1.26–2.77). A sensitivity analysis that only
included patients who were alive at the end of the treatment period
gave the same findings.
TTFS at 24 weeks continued to be highly prognostic of OS with
the failures (n¼ 68) having a median OS of 8.3 months (95% CIs:
6.7–12.5) and those failure free (n¼ 172) having a median OS of
42.3 months (95% CIs: 35.9–48.8).
Table 1. Univariable and multivariable Cox regression analysis of OS
OS (months) Univariable Multivariable
n Median 95% CIs HR 95% CIs P-value HR 95% CIs P-value
Trial arm
CRT only 129 34.5 24.7–42.3 1 1
CRTþ cetuximab 129 24.7 18.6–31.3 1.25 0.93–1.69 0.137 1.15 0.84–1.57 0.388
Age
o65 109 36.7 24.9–43.6 1 1
X65 149 24.5 19.7–30.1 1.36 1.00–1.85 0.047 1.32 0.95–1.84 0.093
Reason for no surgery
Patient choice 97 31.3 24.0–44.0 1 1
Local extent of disease 122 24.7 18.6–34.5 1.2 0.86–1.68 0.276 0.97 0.67–1.41 0.875
Comorbidity/poor PS 39 31.6 14.8–42.7 1.25 0.81–1.94 0.318 0.98 0.58–1.67 0.949
Sex
Female 113 34.6 24.7–48.8 1 1
Male 145 24.9 19.6–31.6 1.44 1.06–1.95 0.02 1.35 0.96–1.90 0.083
WHO status
0 131 30.3 24.0–38.4 1 1
1 127 24.9 19.2–34.3 1.14 0.84–1.53 0.405 1.07 0.77–1.50 0.675
Stage
I or II 103 42.4 31.3–49.9 1 1
III 155 24 18.6–26.8 1.65 1.20–2.27 0.002 1.52 1.05–2.21 0.028
Tumor type
Squamous 188 28.4 24.0–38.0 1 1
Adeno/undiff 70 24.9 15.9–35.1 1.24 0.90–1.72 0.192 1.01 0.67–1.52 0.961
Full radiation dose
Yes 217 34.3 25.8–39.1 1 1
No 41 10 5.9–18.4 3.19 2.17–4.70 0 2.06 1.21–3.49 0.008
Cisplatin intensity
X75% 182 35.9 27.2–42.4 1 1
o75% 76 16.2 12.5–20.8 2.18 1.59–2.99 0 1.8 1.12–2.89 0.016
Cape/5FU intensity
X75% 172 34.5 25.4–39.4 1 1
o75% 86 20 15.4–24.7 1.66 1.22–2.26 0.001 0.85 0.54–1.34 0.493
Total disease length
o4 cm 56 36 24.7–58.0 1 1
X4–o6 cm 85 37.9 24.0–49.9 0.98 0.63–1.52 0.928 0.98 0.62–1.55 0.928
X6–o8 cm 55 24.9 18.6–40.3 1.46 0.92–2.33 0.107 1.2 0.72–2.00 0.489
X8 cm 62 18.4 14.9–27.8 1.84 1.17–2.89 0.009 1.5 0.91–2.50 0.115
Abbreviations: 5FU¼ Fluorouracil; CI¼ confidence interval; CRT¼ chemoradiotherapy; HR¼ hazard ratio; OS¼overall survival; PS¼performance status; WHO¼World Health Organisation.
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In the dCRTþC arm only, there was no difference in survival
between those with any grade 3þ dermatological toxicity during
treatment (n¼ 28) when compared to those without (n¼ 101)
(HR¼ 1.03, 95% CI: 0.63–1.69, P¼ 0.895).
Progression-free survival. The PFS analysis (Table 2 and
Figure 2C) suggests that the median PFS was still higher in the
dCRT-only arm (24.1 months (95% CIs: 15.3–29.9) vs 15.9 months
(95% CIs: 10.7–20.8)), although the HR was still not significant on
either univariable or multivariable analysis (HR¼ 1.28; 95% CIs:
0.94–1.75; P¼ 0.114 and HR¼ 1.20; 95% CIs: 0.87–1.66; P¼ 0.220,
respectively). Higher stage, male sex, and lower cisplatin dose
intensity were associated with worse PFS in multivariable analysis.
A sensitivity analysis that only included patients who were alive at
the end of the treatment period gave the same findings.
Similar results were seen in LPFS (infield), LPFS (outfield), and
DPFS (Figure 2D–F). The median LPFS (infield) was better in the
dCRT arm and this approached statistical significance: 27.9
months (95% CIs: 19.2–51.7) vs 20.0 months (95% CIs:
11.1–26.1), HR¼ 1.36 (95% CIs: 0.99–1.87, P¼ 0.062). Differences
in LPFS (outfield) and DPFS also favoured the dCRT arm although
with no statistical significance; median LPFS (outfield): 35.9
months (24.7–62.1) vs 21.5 months (16.3–33.0), HR¼ 1.32
(0.94–1.85), P¼ 0.112; median DPFS: 29.3 months (19.3–60.6) vs
23.5 months (15.9–35.8), HR¼ 1.24 (0.89–1.73), P¼ 0.207. In the
multivariable models for LPFS (infield), LPFS (outfield), and DPFS,
only less than full protocol radiotherapy dose and lower cisplatin
dose intensity remained significant at the Po0.05 level (data not
shown).
Patterns of first progression. The patterns of first progression are
shown in Table 3. There were 77 progressions prior to death or
date last seen in the dCRT arm and 85 in the dCRTþC group.
More progressions involved a distant progression only (76 out of
162 (46.9%)) compared to loco-regional progression only (57 out
of 162 (35.2%)). In the dCRT arm, out of 38 patients with a loco-
regional progression, 31 progressed within the RT field compared
to 40 out of 48 in the dCRTþC group (81.6% vs 83.3%,
respectively, w2¼ 0.0453, P¼ 0.831). Very similar patterns were
seen in both squamous cell and adenocarcinoma/undifferentiated
tumours (Supplementary Table S2).
Causes of death. At the time of analysis, 84 (65.1%) patients had
died (69 (53.5%) of oesophageal cancer) in the dCRT arm and 90
(69.8%) patients had died (78 (60.5%) of oesophageal cancer) in
the dCRTþC arm (Supplementary Table S3).
DISCUSSION
These long-term data, analysed after death of nearly two-thirds of
the patients in both arms and after a median follow-up of 46.2
months in surviving patients, show that median OS in the dCRT
arm (34.5 months (95% CI: 24.7–42.3)) is better than initially
reported. Although survival in the standard dCRT arm remained
superior to the cetuximab arm, the difference was no longer
statistically significant. Local progression within radiation field was
higher in the cetuximab arm, which approached statistical
significance (P¼ 0.062); full-dose radiotherapy and a cisplatin
dose intensity of475% were associated with improved survival in
the multivariable model. Long-term residual treatment toxicity was
very low and TFFS remained a highly significant surrogate for OS.
A difference in treatment effect was found by sex with the better
survival in the dCRT arm not being seen in females; however, this
was an exploratory analysis for which we do not have a hypothesis
and may be due to chance, therefore further corroboration is
needed (Wallach et al, 2016).
At the time of initiating this study, there was significant
interest in combining radiotherapy with cetuximab following
reported survival advantage for this combination in a rando-
mised controlled trial in head and neck cancer, which showed
near doubling of median OS (54 vs 28 months, P¼ 0.02) and
improved 3-year OS (57 vs 44%; Bonner et al, 2006). Preclinical
data suggested radioresistance in EGFR overexpressing head and
neck cell lines and this radioresistance could be reversed through
EGFR blockade (Akimoto et al, 1999; Huang et al, 1999, 2002;
Bonner et al, 2000; Milas et al, 2000, 2004; Harari and Huang,
2001; Nasu et al, 2001; Shintani et al, 2003). Subsequent to
SCOPE-1, several other studies have reported outcomes from
EGFR inhibition and CRT in oesophageal cancer (Ruhstaller
et al, 2011; Becerra et al, 2013; Meng et al, 2013; Ubink et al,
2014). Most notably, the RTOG 0436 trial randomised 344
patients to weekly paclitaxel, cisplatin with or without cetuximab
and 50.4 Gy of radiotherapy. The study failed to demonstrate
improvements in OS, local control, or clinical complete response
rate (Suntharalingam et al, 2014).
The inability to deliver adequate doses of standard chemora-
diotherapy treatment has been a consistent feature of randomised
trials of cetuximab in head and neck, and GI cancer which may have
contributed to inferior outcomes in the cetuximab arms (Maughan
et al, 2011; Waddell et al, 2013; Ang et al, 2014). In RTOG 0522, a
trial designed to test the benefits for the addition of cetuximab to
chemoradiotherapy in squamous cell head and neck cancer, patients
receiving cetuximab experienced more interruptions to radiotherapy
treatment and no survival advantage. The findings from the SCOPE-
1 trial are consistent with these observations.
Despite the lack of benefit from the addition of cetuximab, it is
important to report long-term outcomes of dCRT trials, as mature
survival data using this modality in oesophageal cancer are lacking.
Although a significant proportion of patient was elderly (39%
above the age of 70 years), the majority had stage 3 disease (60%),
and most patients were unsuitable for surgery due to advanced
local disease (47%) and/or co-morbidities (16%); the OS in the
standard arm of this study is among the best in published literature
on dCRT (Cooper et al, 1999; Stahl et al, 2005; Bedenne et al, 2007;
Herskovic et al, 2012; Conroy et al, 2014). The encouraging
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Figure 3. Hazard ratio plots for treatment effect on overall survival by
baseline characteristics (HR41 favours dCRT only).
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long-term survival seen in SCOPE-1 reassures us that dCRT is
not an unreasonable alternative to surgery, particularly in patients
with borderline fitness where surgery is considered a high-risk
procedure. In addition, local recurrence, often raised as an
important weakness of dCRT over surgery, was lower in this trial
when compared with other historic reports of dCRT (Minsky et al,
2002; Denham et al, 2003; Herskovic et al, 2012).
So what factors are likely to have contributed to the good
outcome seen in the dCRT arm of this trial compared to historic
studies? For the first time in the United Kingdom, this trial
introduced a detailed protocol for staging patients with oesopha-
geal cancer due to undergoing non-surgical treatment, thereby
improving patient selection – all eligible patients had an EUS and
85% were staged with 18F-FDG CT-PET. It also introduced what,
at the time, was advanced, conformal radiotherapy treatment by
way of a detailed radiotherapy planning guidance document
together with a RTQA programme (Gwynne et al, 2013). The
authors believe such RTQA programmes, which included pre-trial
test case and real-time radiotherapy planning reviews in a
proportion of patients, would have contributed to the improved
outcomes and should become a mandatory component of future
radiotherapy trials (Ibbott et al, 2013).
Treatments after the end of trial chemoradiotherapy were not
accounted for in the analysis and therefore the impact of second-
and subsequent-line therapies on OS cannot be ascertained.
Moreover, no imaging was mandated after 24 weeks and detection
of progression relied on clinical assessment at follow-up visits –
mandating serial imaging may have led to earlier detection of disease
progression and therefore earlier institution of second-line treat-
ment. Nevertheless, this mirrors standard of care for this patient
population and there is little evidence for a survival advantage for
any treatment intervention over another post dCRT.
The failure of SCOPE-1 and other cetuximab-based studies
argues against the non-selective use of biological agents in
oncology trials, highlighting the potential for harm and not just
lack of efficacy. The use of a less toxic chemotherapy backbone
may also allow incorporation of novel agents into dCRT regimens
without compromising dose intensity of conventional treatment.
The weekly carboplatin-/paclitaxel-based neo-adjuvant CRT regi-
men, as established by the CROSS trial Shintani et al, 2003,
reported low incidence of treatment-related toxicity and an
impressive pathological complete response of about 50% in the
squamous cell subtype – such low-toxicity regimens should be
explored in the context of dCRT trials in oesophageal cancer.
Table 2. Univariable and multivariable Cox regression analysis of PFS
PFS (months) Univariable Multivariable
n Median CI HR 95% CIs P-value HR 95% CIs P-value
Trial arm
CRT only 129 24.1 15.3–29.9 1 1
CRTþ cetuximab 129 15.9 10.7–20.8 1.29 0.94–1.75 0.111 1.22 0.89–1.69 0.22
Age
o65 109 24.2 15.4–43.2 1 1
X65 149 15.5 11.3–20.6 1.33 0.97–1.83 0.076 1.3 0.92–1.83 0.134
Reason for no surgery
Patient choice 97 20.8 15.9–28.6 1 1
Local extent of disease 122 15.3 11.5–24.2 1.15 0.82–1.62 0.409 0.93 0.64–1.35 0.7
Comorbidity/poor PS 39 17.6 9.3–51.7 1.15 0.71–1.85 0.566 0.78 0.44–1.36 0.378
Sex
Female 113 22.6 14.9–51.8 1 1
Male 145 15.9 11.3–22.9 1.44 1.05–1.97 0.024 1.43 1.02–2.01 0.039
WHO status
0 131 22.6 15.3–28.6 1 1
1 127 15.5 10.8–21.1 1.14 0.84–1.55 0.412 1.23 0.88–1.72 0.233
Stage
I or II 103 28.6 16.7–60.6 1 1
III 155 14.2 10.9–20.8 1.5 1.09–2.08 0.014 1.48 1.02–2.15 0.038
Tumor type
Squamous 188 20 15.1–27.8 1 1
Adeno/undiff 70 15.3 10.4–20.6 1.32 0.94–1.85 0.115 1.1 0.72–1.69 0.652
Full radiation dose
Yes 219 20 15.9–27.9 1 1
No 39 6.1 3.4–11.0 2.59 1.64–4.08 0 1.71 0.97–3.00 0.062
Cisplatin intensity
X75% 183 22.9 16.4–29.9 1 1
o75% 75 10.7 8.4–15.6 1.99 1.42–2.77 0 1.97 1.24–3.12 0.004
Cape/5FU intensity
X75% 174 20.8 15.5–28.6 1 1
o75% 84 13.8 8.2–20.6 1.44 1.04–2.00 0.029 0.82 0.53–1.28 0.38
Total disease length
o4 cm 56 23.5 11.1-. 1 1
X4–o6 cm 85 23.2 15.4–62.3 0.96 0.61–1.53 0.877 0.89 0.55–1.43 0.626
X6–o8 cm 55 13.8 8.4–25.4 1.51 0.93–2.45 0.095 1.37 0.80–2.34 0.252
X8 cm 62 12.8 10.0–20.0 1.57 0.99–2.51 0.058 1.25 0.74–2.09 0.405
Abbreviations: 5FU¼ Fluorouracil; CI¼ confidence interval; CRT¼ chemoradiotherapy; HR¼hazard ratio; PFS¼progression-free survival; PS¼performance status; WHO¼World Health
Organisation.
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In summary, we concur with our previous report that cetuximab
should not be used as standard with CRT in the treatment of
oesophageal cancer. This mature analysis highlighted the excellent
survival and low rate of long-term toxicity of standard dCRT,
which taken in conjunction with the early return of quality of
life (Rees et al, 2015), suggests dCRT is an effective treatment
modality. Given the competing risks of systemic and local failure,
efforts should continue to maximise local control through radio-
therapy dose intensification (in the context of modern day
radiotherapy planning and delivery) and to identify more effective
systemic treatments for those patients who do not, or are unlikely
to, respond to conventional dCRT. Such an approach, including
radiotherapy dose escalation and individualisation of systemic
therapy through early PET response will be pursued in Cancer
Research UK-funded SCOPE-2 trial, currently in set up in the
United Kingdom (EudraCT No: 2015–001740–11).
ACKNOWLEDGEMENTS
The SCOPE-1 trial was sponsored by Velindre NHS Trust. We
thank all the patients who participated in the trial, the doctors,
nurses, pathologists, and other members of the MDTs; the
radiotherapy team and the research team from the participating
centres. We would like to thank members of the Independent Data
Monitoring Committee and the Independent Trial Steering
Committee for their oversight of the trial. This work was supported
by Cancer Research UK (grant number C20177/A7256) and
Cancer Research UK core funding at Wales Cancer Trials Unit.
Merck provided free cetuximab, labelling, and distribution for the
study. The RTTQA was funded by Cancer Research UK and the
Cardiff NCRI RTTQA Center at Velindre NHS Trust who are
funded by the Health and Social Care Research Wales, and
Department of Health (England). SM is funded by NIHR Oxford
Biomedical Research Centre and the CRUK Experimental Cancer
Medicines Centre, Oxford.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L (1999)
Inverse relationship between epidermal growth factor receptor expression
and radiocurability of murine carcinomas. Clin Cancer Res 5(10):
2884–2890.
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS,
Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC,
Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ,
Yom SS, Axelrod RS (2014) Randomized phase III trial of concurrent
accelerated radiation plus cisplatin with or without cetuximab for stage III
to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32(27):
2940–2950.
Becerra CR, Hanna N, McCollum AD, Becharm N, Timmerman RD,
DiMaio M, Kesler KA, Yu M, Yan T, Choy H (2013) A phase II study with
cetuximab and radiation therapy for patients with surgically resectable
esophageal and GE junction carcinomas: Hoosier Oncology Group
G05-92. J Thorac Oncol 8(11): 1425–1429.
Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, Pezet D,
Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F, Binquet C
(2007) Chemoradiation followed by surgery compared with
chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.
J Clin Oncol 25(10): 1160–1168.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU,
Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H,
Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for
squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):
567–578.
Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA,
Buchsbaum DJ, Saleh MN, Stackhouse MA, LoBuglio AF, Peters GE,
Carroll WR, Waksal HW (2000) Enhanced apoptosis with combination
C225/radiation treatment serves as the impetus for clinical investigation in
head and neck cancers. J Clin Oncol 18(21 Suppl): 47S–53S.
Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY,
Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C,
Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A,
Federation Francophone de Cancerologie D, Group U-G (2014) Definitive
chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in
patients with oesophageal cancer (PRODIGE5/ACCORD17): final results
of a randomised, phase 2/3 trial. Lancet Oncol 15(3): 305–314.
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson Jr JA, Al-Sarraf M,
Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV,
Leichman LL (1999) Chemoradiotherapy of locally advanced esophageal
cancer: long-term follow-up of a prospective randomized trial (RTOG
85-01). Radiation Therapy Oncology Group. JAMA 281(17):
1623–1627.
Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R,
Bashir N, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R,
Maughan T, Griffiths G (2013) Chemoradiotherapy with or without
cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre,
phase 2/3 randomised trial. Lancet Oncol 14(7): 627–637.
Denham JW, Steigler A, Kilmurray J, Wratten C, Burmeister B, Lamb DS,
Joseph D, Delaney G, Christie D, Jamieson G, Smithers BM, Ackland S,
Walpole E (2003) Relapse patterns after chemo-radiation for carcinoma of
the oesophagus. Clin Oncol (R Coll Radiol) 15(3): 98–108.
Gwynne S, Spezi E, Sebag-Montefiore D, Mukherjee S, Miles E, Conibear J,
Staffurth J, Ncri Rttqa O, Imaging S (2013) Improving radiotherapy
quality assurance in clinical trials: assessment of target volume
delineation of the pre-accrual benchmark case. Br J Radiol 86:
20120398.
Harari PM, Huang SM (2001) Head and neck cancer as a clinical model for
molecular targeting of therapy: combining EGFR blockade with radiation.
Int J Radiat Oncol Biol Phys 49(2): 427–433.
Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M (2012) Esophageal
carcinoma advances in treatment results for locally advanced disease:
review. Ann Oncol 23(5): 1095–1103.
Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor
blockade with C225 modulates proliferation, apoptosis, and
radiosensitivity in squamous cell carcinomas of the head and neck. Cancer
Res 59(8): 1935–1940.
Table 3. Patterns of first progression in relation to radiation target volumes (number of events) by trial arm
dCRT dCRTþC
Infield Outfield Both Infield Outfield Both
n % n % n % n % n % n %
Loco-regional only 19 24.7 3 3.9 5 6.5 19 22.4 5 5.9 6 7.1
Loco-regional plus distant 5 6.5 4 5.2 2 2.6 10 11.8 3 3.5 5 5.9
Distant only 39 50.6 37 43.5
Total 24 31.2 46 59.7 7 9.1 29 34.1 45 52.9 11 12.9
Abbreviation: dCRT¼definitive chemoradiotherapy. Note: Percentages calculated using total number of progressions (77 in dCRT, 85 in dCRTþC) as denominator.
Long-term results from SCOPE-1 BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.21 715
Huang SM, Li J, Armstrong EA, Harari PM (2002) Modulation of radiation
response and tumor-induced angiogenesis after epidermal growth factor
receptor inhibition by ZD1839 (Iressa). Cancer Res 62(15): 4300–4306.
Hurt CN, Nixon LS, Griffiths GO, Al-Mokhtar R, Gollins S, Staffurth JN,
Phillips CJ, Blazeby JM, Crosby TD (2011) SCOPE1: a randomised phase
II/III multicentre clinical trial of definitive chemoradiation, with or
without cetuximab, in carcinoma of the oesophagus. BMC Cancer 11: 466.
Ibbott GS, Haworth A, Followill DS (2013) Quality assurance for clinical trials.
Front Oncol 3: 311.
Loibl S, Skacel T, Nekljudova V, Luck HJ, Schwenkglenks M, Brodowicz T,
Zielinski C, von Minckwitz G (2011) Evaluating the impact of relative total
dose intensity (RTDI) on patients’ short and long-term outcome in
taxane- and anthracycline-based chemotherapy of metastatic breast
cancer- a pooled analysis. BMC Cancer 11: 131.
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH,
Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A,
Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D,
Kaplan R, Cheadle JP, Investigators MCT (2011) Addition of cetuximab to
oxaliplatin-based first-line combination chemotherapy for treatment of
advanced colorectal cancer: results of the randomised phase 3 MRC COIN
trial. Lancet 377(9783): 2103–2114.
Meng X, Wang J, Sun X, Wang L, Ye M, Feng P, Zhu G, Lu Y, Han C, Zhu S,
Liao Z, Yu J (2013) Cetuximab in combination with chemoradiotherapy in
Chinese patients with non-resectable, locally advanced esophageal
squamous cell carcinoma: a prospective, multicenter phase II trial.
Radiother Oncol 109(2): 275–280.
Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor
receptor and tumor response to radiation: in vivo preclinical studies. Int J
Radiat Oncol Biol Phys 58(3): 966–971.
Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J,
Fan Z (2000) In vivo enhancement of tumor radioresponse by C225
antiepidermal growth factor receptor antibody. Clin Cancer Res 6(2): 701–708.
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R,
Okawara G, Rosenthal SA, Kelsen DP (2002) INT 0123 (Radiation
Therapy Oncology Group 94-05) phase III trial of combined-modality
therapy for esophageal cancer: high-dose versus standard-dose radiation
therapy. J Clin Oncol 20(5): 1167–1174.
Nasu S, Ang KK, Fan Z, Milas L (2001) C225 antiepidermal growth factor
receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol
Phys 51(2): 474–477.
Radiation Therapy Oncology Group (2007) RTOG/EORTC Late Radiation
Morbidity Scoring Schema. Available at http://www.rtog.org/
ResearchAssociates/AdverseEventReporting/
RTOGEORTCLateRadiationMorbidityScoringSchema.aspx.
Rees J, Hurt CN, Gollins S, Mukherjee S, Maughan T, Falk SJ, Staffurth J,
Ray R, Bashir N, Geh JI, Cunningham D, Roy R, Bridgewater J,
Griffiths G, Nixon LS, Blazeby JM, Crosby T (2015) Patient-reported
outcomes during and after definitive chemoradiotherapy for oesophageal
cancer. Br J Cancer 113(4): 603–610.
Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P,
Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W,
Widmer L, Inauen R, Brauchli P, Hess V (2011) Cetuximab in
combination with chemoradiotherapy before surgery in patients with
resectable, locally advanced esophageal carcinoma: a prospective,
multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 29(6): 626–631.
Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of
failure time. Control Clin Trials 17(4): 343–346.
Shintani S, Li C, Mihara M, Terakado N, Yano J, Nakashiro K,
Hamakawa H (2003) Enhancement of tumor radioresponse by
combined treatment with gefitinib (Iressa, ZD1839), an epidermal
growth factor receptor tyrosine kinase inhibitor, is accompanied by
inhibition of DNA damage repair and cell growth in oral cancer. Int J
Cancer 107(6): 1030–1037.
Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B,
Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H
(2005) Chemoradiation with and without surgery in patients with locally
advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23(10):
2310–2317.
Suntharalingam M, Winter K, Ilson D, Dicker AP, Kachnic LA, Konski AA,
Chakravarthy B, Anker CJ, Thakrar H, Horiba N, Kavadi V, Deutsch M,
Raben A, Roof M, Videtic G, Pollack J, Safran H, Crane CH (2014) The
initial report of local control on RTOG 0436: a phase 3 trial evaluating the
addition of cetuximab to paclitaxel, cisplatin, and radiation for patients
with esophageal cancer treated without surgery. Int J Radiat Oncol Biol
Phys 90(1): S3.
Ubink I, van der Sluis P, Schipper M, Reerink O, Voest E, Borel-Rinkes I,
Wijrdeman H, Vleggaar F, Agterof M, Overkleeft E, Siersema P,
van Hillegersberg R, Lolkema MP (2014) Adding preoperative
radiotherapy plus cetuximab to perioperative chemotherapy for resectable
esophageal adenocarcinoma: a single-center prospective phase II trial.
Oncologist 19(1): 32–33.
Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C,
Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W,
Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C,
Barbachano Y (2013) Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Lancet Oncol 14(6): 481–489.
Wallach JD, Sullivan PG, Trepanowski JF, Steyerberg EW, Ioannidis JP (2016)
Sex based subgroup differences in randomized controlled trials: empirical
evidence from Cochrane meta-analyses. BMJ 355: i5826.
This work is licensed under the Creative Commons
Attribution 4.0 International License. To view a copy
of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) named above 2017
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
BRITISH JOURNAL OF CANCER Long-term results from SCOPE-1
716 www.bjcancer.com |DOI:10.1038/bjc.2017.21
